FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3165117590> ?p ?o ?g. }

• W3165117590 endingPage "1388" @default.
• W3165117590 startingPage "1387.3" @default.
• W3165117590 abstract "Background: At the moment, a highly relevant issue is the course of SARS-CoV-2 infection in patients with rheumatic pathology, especially, those receiving therapy with biological disease modifying antirheumatic drugs. Objectives: of the current study to assess the prevalence and course of SARS-CoV-2 infection in patients receiving various biological disease modifying antirheumatic drugs. Methods: to assess the severity of the course of SARS-CoV-2, discharged epicrisis from hospitals or the conclusion of computed tomography were used. The average age of the patients ranged from 41.4 + 11.6 years. In the evaluated sample, 47 patients (49.47%) were males. Among the infected of SARS-CoV-2 were patients with rheumatoid arthritis - 45 (47.4%), spondyloarthritis - 39 (41.1%), systemic connective tissue diseases - 11 (11.5%). Results: Since March 2020, among the 1319 patients with rheumatic diseases observed at the St. Petersburg Center of therapy biological disease modifying antirheumatic drugs, 95 patients (7,2%) had SARS-CoV-2 infection. In 57,9% (55 patients) there was a mild course of infection, in 35,8% of cases (34 patients) - a moderate course, in 6,3% (6 patients) - a severe course. Inpatient treatment was received by 29,5% (28 patients). A favorable outcome was noted in 95.8%, and a lethal outcome in 4,2%. The use of interleukin-6 inhibitors was required in 2,1% of patients (2) due to the development of a cytokine storm. The structure of the received biological therapy in the severity of the course is shown in Table 1. Table 1. The structure of the received biological therapy in the severity of the course SARS-CoV-2 infection Mild course CT-1 (<25%) CT-2 (25-50%) CT-3 (50-75%) CT-4 (>75%) TNF-α inhibitors, n (%) 30 (31,6) 11 (11,6) 7 (7,3) 3 (3,2) 0 (0,0) anti B-cell therapy (rituximab), n (%) 2 (2,1) 1 (1,1) 2 (2,1) 1 (1,1) 2 (2,1) Abatacept, n (%) 3 (3.2) 0 (0,0) 2 (2,1) 0 (0,0) 0 (0,0) Janus kinase inhibitors, n (%) 5 (5,3) 1 (1,1) 1 (1,1) 0 (0,0) 0 (0,0) Interleukin-6 inhibitors, n (%) 6 (6,3) 0 (0,0) 0 (0,0) 0 (0,0) 0 (0,0) Interleukin-17 inhibitors, n (%) 8 (8,4) 2 (2,1) 2 (2,1) 0 (0,0) 0 (0,0) Other, n (%) 1 (1,1) 4 (4,2) 1 (1,1) 0 (0,0) 0 (0,0) Among 95 infected patients, who were observed in the center, 51 received therapy with TNF-α inhibitors (8.5% of the total number of patients receiving therapy), 8 - rituximab therapy (2.7%), 5 - abatacept (6.3%), 7 - Janus kinase inhibitors (0.9%), 6 – interleukin-6 inhibitors (9.2), 12 - interleukin -17 inhibitors (14.1%), 6 patients treated with other drugs (10%). Conclusion: Taking into account the SARS-CoV-2 pandemic, further study of the course of infection in patients with rheumatic diseases, including those receiving biological therapy, is required. More information is also needed on the safety and efficacy of vaccination in this patient population. Disclosure of Interests: None declared" @default.
• W3165117590 created "2021-06-07" @default.
• W3165117590 creator A5002259667 @default.
• W3165117590 creator A5011776463 @default.
• W3165117590 creator A5030102360 @default.
• W3165117590 creator A5090064951 @default.
• W3165117590 date "2021-05-19" @default.
• W3165117590 modified "2023-09-26" @default.
• W3165117590 title "AB0712 THE INCIDENCE OF SARS-СOV-2 INFECTION IN PATIENTS WITH RHEUMATIC DISEASES ON THERAPY BIOLOGICAL DISEASE MODIFYING ANTIRHEUMATIC DRUGS" @default.
• W3165117590 doi "https://doi.org/10.1136/annrheumdis-2021-eular.4323" @default.
• W3165117590 hasPublicationYear "2021" @default.
• W3165117590 type Work @default.
• W3165117590 sameAs 3165117590 @default.
• W3165117590 citedByCount "0" @default.
• W3165117590 crossrefType "journal-article" @default.
• W3165117590 hasAuthorship W3165117590A5002259667 @default.
• W3165117590 hasAuthorship W3165117590A5011776463 @default.
• W3165117590 hasAuthorship W3165117590A5030102360 @default.
• W3165117590 hasAuthorship W3165117590A5090064951 @default.
• W3165117590 hasBestOaLocation W31651175901 @default.
• W3165117590 hasConcept C120665830 @default.
• W3165117590 hasConcept C121332964 @default.
• W3165117590 hasConcept C126322002 @default.
• W3165117590 hasConcept C198451711 @default.
• W3165117590 hasConcept C2776670291 @default.
• W3165117590 hasConcept C2777077863 @default.
• W3165117590 hasConcept C2777178219 @default.
• W3165117590 hasConcept C2777575956 @default.
• W3165117590 hasConcept C2779075594 @default.
• W3165117590 hasConcept C2779134260 @default.
• W3165117590 hasConcept C2908564923 @default.
• W3165117590 hasConcept C2908701176 @default.
• W3165117590 hasConcept C2909063479 @default.
• W3165117590 hasConcept C500440147 @default.
• W3165117590 hasConcept C61511704 @default.
• W3165117590 hasConcept C71924100 @default.
• W3165117590 hasConceptScore W3165117590C120665830 @default.
• W3165117590 hasConceptScore W3165117590C121332964 @default.
• W3165117590 hasConceptScore W3165117590C126322002 @default.
• W3165117590 hasConceptScore W3165117590C198451711 @default.
• W3165117590 hasConceptScore W3165117590C2776670291 @default.
• W3165117590 hasConceptScore W3165117590C2777077863 @default.
• W3165117590 hasConceptScore W3165117590C2777178219 @default.
• W3165117590 hasConceptScore W3165117590C2777575956 @default.
• W3165117590 hasConceptScore W3165117590C2779075594 @default.
• W3165117590 hasConceptScore W3165117590C2779134260 @default.
• W3165117590 hasConceptScore W3165117590C2908564923 @default.
• W3165117590 hasConceptScore W3165117590C2908701176 @default.
• W3165117590 hasConceptScore W3165117590C2909063479 @default.
• W3165117590 hasConceptScore W3165117590C500440147 @default.
• W3165117590 hasConceptScore W3165117590C61511704 @default.
• W3165117590 hasConceptScore W3165117590C71924100 @default.
• W3165117590 hasIssue "Suppl 1" @default.
• W3165117590 hasLocation W31651175901 @default.
• W3165117590 hasOpenAccess W3165117590 @default.
• W3165117590 hasPrimaryLocation W31651175901 @default.
• W3165117590 hasRelatedWork W1838548883 @default.
• W3165117590 hasRelatedWork W2017587912 @default.
• W3165117590 hasRelatedWork W2027968917 @default.
• W3165117590 hasRelatedWork W2607130235 @default.
• W3165117590 hasRelatedWork W2953955431 @default.
• W3165117590 hasRelatedWork W2996380604 @default.
• W3165117590 hasRelatedWork W4234547310 @default.
• W3165117590 hasRelatedWork W4239841759 @default.
• W3165117590 hasRelatedWork W4378172486 @default.
• W3165117590 hasRelatedWork W3087746849 @default.
• W3165117590 hasVolume "80" @default.
• W3165117590 isParatext "false" @default.
• W3165117590 isRetracted "false" @default.
• W3165117590 magId "3165117590" @default.
• W3165117590 workType "article" @default.